Clinical features and survival analysis of different subtypes of patients with breast cancer brain metastases

Chinese Journal of Cancer

Volumn 29, Issue 4, 2010, Pages 413-419

  Bai, Bing ^a   Yuan, Zhong Yu ^a   Liu, Dong Geng ^a   Teng, Xiao Yu ^a   Wang, Shu Sen ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Brain metastases; Breast cancer; HER 2; Prognosis; Survival; Triple negative

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE ANTIBIOTIC AGENT; BEVACIZUMAB; CAPECITABINE; CISPLATIN DERIVATIVE; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; EXEMESTANE; FLUOROURACIL; GEFITINIB; GEMCITABINE; LAPATINIB; LETROZOLE; METHOTREXATE; NAVELBINE; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; WHOLE BRAIN RADIOTHERAPY;

EID: 79955865582     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.009.10643     Document Type: Article

References (25)

1. Barnholtz-Sloan JS, Sloan AE, Davis FG, et al. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System [J]. J Clin Oncol, 2004,22(14):2865-2872.
2. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer [J]. J Clin Oncol, 2004,22(17):3608-3617.
3. Patanaphan V, Salazar OM, Risco R. Breast cancer: Metastatic patterns and their prognosis [J]. South Med J, 1988,81(9):1109-1112.
4. Tsukada Y, Fouad A, Pickren JW, et al. Central nervous system metastasis from breast carcinoma. Autopsy study [J]. Cancer, 1983,52 (12):2349-2354.
5. Lin NU, Claus E, Sohl J, et al. Sites of Distant recurrence and clinical outcomes in patients with metastatic triple-ne gative beast cancer [J]. Cancer, 2008,113(10):2638-2645.
6. Dawood S, Broglio K, Esteva FJ, et al. Survival among women with triple receptor-ne gative breast cancer and brain metastases [J]. Ann Oncol, 2009,20(4):621-627.
7. Nam BH, Kim SY, Han HS, et al. Breast cancer subtypes and survival in patients with brain metastases [J]. Breast Cancer Res, 2008,10(1):R20.
8. Gabos Z, Sinha R, Hanson J, et al. Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer [J]. J Clin Oncol, 2006,24(36):5658-5663.
9. Pestalozzi BC, Zahrieh D, Price KN, et al. Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG) [J]. Ann Oncol, 2006,17(6):935-944.
10. Hicks DG, Short SM, Prescott NL, et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and over express HER2 or EGFR [J]. Am J Surg Pathol, 2006,30(9):1097-1104.
11. Tham, YL, Sexton K, Kramer R, et al. Primary breast cancer phenotypes associated with propensity for central nervous system metastases [J]. Cancer, 2006,107(10):2521-2522.
12. Perou CM, Srlie T, Eisen MB, et al. Molecular portraits of human breast tumors [J]. Nature, 2000,406(6797):747-752.
13. Miller KD, Weathers T, Haney LG, et al. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival [J]. Ann Oncol, 2003,14 (7):1072-1077.
14. Fenner MH, Possinger K. Chemotherapy for breast cancer brain metastases [J]. Onkologie, 2002,25(5):474-479.
15. Ekenel M, Hormigo AM, Peak S, et al. Capecitabine therapy of central nervous system metastases from breast cancer [J]. Neurooncol, 2007,85 (2):223-227.
16. Chargari C, Kirova YM, Diéras V, et al. Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients [J]. J Neurooncol, 2009,93(3):379-384.
17. Fabi A, Vidiri A, Ferretti G, et al. Dramatic regression of multiple brain metastases from breast cancer with Capecitabine. another arrow at the bow [J]. Cancer Invest, 2006,24(4):466-468.
18. Wang ML, Yung WK, Royce ME, et al. Capecitabine for 5-flu orouracil- resistant brain metastases from breast cancer [J]. Am J Clin Oncol, 2001,24(4):421-424.
19. Lin NU, Carey LA, Liu MC, et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2- positive breast cancer [J]. J Clin Oncol, 2008,26(12):1993-1999.
20. Lin NU, Diéras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-po sitive breast cancer [J]. Clin Cancer Res, 2009,15(4):1452-1459.
21. Chidel MA, Suh JH, Reddy CA, et al.Application of the recursive partitioning analysis and evaluation of the use of whole brain radiation among patients treated with stereotaetic radiosurgery for newly diagnosed brain metastases [J]. Int J Radiat Oncol Biol Phys, 2000,47(4):993-999.
22. Firlik KS, Kondziolka D, Flickinger JC, et al.St ereotactic radiosurgery for brain metastases from breast cancer [J]. Ann Surg Oncol, 2000,7 (5): 333-338.
23. Carey RW, Davis JM, Zervas NT. Tamoxifen-induced regression of cerebral metastases in breast carcinoma [J]. Cancer Treat Rep, 1981,65 (9-10):793-795.
24. Madhup R, Kirti S, Bhatt ML, et al. Letrozole for brain and scalp metastases from breast cancer-a case report. [J]. Breast, 2006,15(3): 440-442.
25. Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-ce ll lung cancer [J]. N Engl J Med, 2007,357(7):664-672.